In a new Federal Register filing set to be published soon, the Drug Enforcement Agency is moving to more than quintuple the amount of cannabis that can legally be grown in the U.S. for research purposes—from roughly 1,000 pounds in 2018 to more than 5,400 pounds next year.
At the same time, DEA is also pushing to reduce the amount of certain opioid drugs—such as oxycodone, hydrocodone, morphine, fentanyl and others—that are produced in the U.S.
The proposed quotas for cannabis and other drugs “reflects the total amount of controlled substances necessary to meet the country’s medical, scientific, research, industrial, and export needs for the year and for the establishment and maintenance of reserve stocks,” DEA said.
The DEA’s huge increase in marijuana production quotas for 2019 could be a sign that it anticipates eventual approval of some of the additional grower applications, or it could just indicate that reserve stocks are getting low and that it’s time to re-up the federal cannabis stash.
See the original article at Forbes